Quantcast

Latest Insulin glargine Stories

2014-09-16 08:29:41

Clinical Trials Mark Important Milestone in Development of Two Highly Complex Products PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus® and its insulin analog to Sanofi's Lantus®. http://photos.prnewswire.com/prnvar/20140423/77793 In October 2014, Mylan will commence a Phase III...

2014-09-04 08:30:19

Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators INDIANAPOLIS, Sept. 4, 2014 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus(®)) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these...

2014-08-18 20:21:55

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company (NYSE: LLY) and...

2014-07-08 08:31:22

- Toujeo dossier already accepted by EMA - PARIS, July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for...

2014-06-27 08:25:26

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company and Boehringer Ingelheim is the first biosimilar insulin...

2014-06-27 08:25:19

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim is the first...

2014-06-16 20:22:11

AWARD-2: Once-Weekly Dulaglutide 0.75 mg Non-Inferior, 1.5 mg Superior in HbA1c Reduction from Baseline with Sustained Weight Loss and Lower Risk for Hypoglycemia SAN FRANCISCO, June 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with a lower risk for hypoglycemia.(1,2) Dulaglutide is an...

2014-06-14 12:21:08

PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus(®) (insulin glargine). Lowering of post-prandial glucose was measured as change...

2014-06-14 12:21:03

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared...

2014-06-14 12:20:43

Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'